Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|December 26, 2022
DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapyJulie Dardare, Andréa Witz, Margaux Betz, et al.
Plos One|January 16, 2020
Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancerClaire Franczak, Andréa Witz, Karen Geoffroy, et al.
Cancers|October 14, 2023
COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19)Valérie Seegers, Guillaume Rousseau, Ke Zhou, et al.
Cancers|October 26, 2024
<i>KRAS</i>, a New Target for Precision Medicine in Colorectal Cancer?Alice Boilève, Cristina Smolenschi, Aurélien Lambert, et al.
Cancers|July 24, 2021
Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients-First Results from the PAPESCO-19 Cohort StudyKe Zhou, Audrey Blanc-Lapierre, Valérie Seegers, et al.
Cancers|November 26, 2022
COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19)Valérie Seegers, Guillaume Rousseau, Ke Zhou, et al.
Clinical Medicine Insights. Oncology|April 25, 2022
COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19)Ke Zhou, Jean-Luc Raoul, Audrey Blanc-Lapierre, et al.
Oncology Letters|November 14, 2025
Sensitive cell-free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM studyAlexandre Harlé, Céline Gavoille, Olivier Bouché, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2026
Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survivalAlice Boilève, Léa Mercier, Baptiste Bonnet, et al.
JAMA Oncology|September 1, 2022
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical TrialThierry Conroy, Florence Castan, Anthony Lopez, et al.
Pageof 5